Expansion of the Pharmaceutical Network

「The Company is expanding its services, including a service for sharing pharmaceutical inventory information by region and various training programs. New memberships progressed steadily, and as of 31 March 2026, the pharmaceutical network had 12,003 members, comprising 472 Group companies and 11,531 general members, an increase of 1,000 from the end of the previous fiscal year.」

「As of 31 March 2026, the pharmaceutical network had 12,003 member locations, comprising 472 locations operated by the Group and 11,531 general member stores, an increase of 1,000 from the end of the previous consolidated fiscal year.」

「In the pharmaceutical network segment, the Company is expanding its services, including a service for sharing pharmaceutical inventory information by region and various training programs. New memberships progressed steadily, and as of 30 September 2025, the pharmaceutical network had 11,511 members, comprising 469 Group companies and 11,042 general members, an increase of 508 from the end of the previous fiscal year.」

「The Company is expanding its services by providing, among other offerings, a service for sharing pharmaceutical inventory information by region and various training programs, and new memberships progressed steadily. As of 31 March 2025, the pharmaceutical network had 11,003 members, comprising 457 Group companies and 10,546 general members, an increase of 1,247 from the end of the previous fiscal year.」

「The Company is expanding its services by providing, among other offerings, a service for sharing pharmaceutical inventory information by region and various training programs, and new memberships progressed steadily. As of 30 September 2024, the pharmaceutical network had 10,435 members, comprising 452 Group companies and 9,983 general members, an increase of 679 from the end of the previous fiscal year.」

「In the pharmaceutical network segment, although new memberships fell short of expectations, they accumulated at a generally steady pace, and members' pharmaceutical transaction volumes increased. As of 30 September 2023, the pharmaceutical network had 9,374 members, comprising 434 Group companies and 8,940 general members, an increase of 462 from the end of the previous fiscal year.」

「As of 30 June 2023, the pharmaceutical network had 9,172 members, comprising 430 Group companies and 8,742 general members, an increase of 260 from the end of the previous fiscal year.」

「In the pharmaceutical network segment, demand for greater operational efficiency at pharmacies increased as pharmacists focused more intensively on face-to-face services, partly due to the impact of revisions to dispensing fees, and new memberships continued to progress solidly. As of 31 December 2022, the pharmaceutical network had 8,555 members, comprising 429 Group companies and 8,126 general members, an increase of 1,154 from the end of the previous fiscal year.」

「As of 30 September 2022, the pharmaceutical network had 8,173 members, comprising 427 Group companies and 7,746 general members, an increase of 772 from the end of the previous fiscal year.」

「As of 30 June 2022, the pharmaceutical network had 7,812 members, comprising 426 Group companies and 7,386 general members, an increase of 411 from the end of the previous fiscal year.」

「As of 31 March 2022, the pharmaceutical network had 7,401 members, comprising 425 Group companies and 6,976 general members, an increase of 1,285 from the end of the previous fiscal year.」

「Against the backdrop of growing demand for management stability, new memberships continued to progress solidly. As of 31 December 2021, the pharmaceutical network had 7,003 members, comprising 424 Group companies and 6,579 general members, an increase of 887 from the end of the previous fiscal year.」

「Against the backdrop of growing demand for management stability, new memberships continued to progress solidly. As of 30 September 2021, the pharmaceutical network had 6,700 members, comprising 419 Group companies and 6,281 general members, an increase of 584 from the end of the previous fiscal year.」

「As of 30 June 2021, the pharmaceutical network had 6,367 members, comprising 417 Group companies and 5,950 general members, an increase of 251 from the end of the previous fiscal year.」

「Against the backdrop of growing demand for more efficient distribution, new memberships continued to progress generally solidly. As of 31 March 2021, the pharmaceutical network had 6,116 members, comprising 416 Group companies and 5,700 general members, an increase of 871 from the end of the previous fiscal year, surpassing a 10% market share.」

「In the pharmaceutical network segment, although some major customers withdrew, new memberships continued to progress generally solidly against the backdrop of growing demand for more efficient distribution. As of 31 December 2020, the pharmaceutical network had 5,745 members, comprising 413 Group companies and 5,332 general members, an increase of 500 from the end of the previous fiscal year.」

「In the pharmaceutical network segment, although some major customers withdrew, new memberships continued to progress solidly against the backdrop of growing demand for more efficient distribution. As of 30 September 2020, the pharmaceutical network had 5,636 members, comprising 409 Group companies and 5,227 general members, an increase of 391 from the end of the previous fiscal year.」

「In the pharmaceutical network segment, new memberships continued to progress solidly against the backdrop of growing demand for more efficient distribution. As of 30 June 2020, the pharmaceutical network had 5,617 members, comprising 415 Group companies and 5,202 general members, an increase of 372 from the end of the previous fiscal year.」

「In the pharmaceutical network segment, new memberships continued to progress steadily against the backdrop of growing demand for more efficient distribution. As of 31 December 2019, the pharmaceutical network had 4,922 members, comprising 421 Group companies and 4,501 general members, an increase of 1,132 from the end of the previous fiscal year.」

「In the pharmaceutical network segment, new memberships continued to progress steadily against the backdrop of growing demand for more efficient distribution. As of 30 September 2019, the pharmaceutical network had 4,560 members, comprising 419 Group companies and 4,141 general members, an increase of 770 from the end of the previous fiscal year.」

「In the pharmaceutical network segment, new memberships continued to progress steadily against the backdrop of growing demand for more efficient distribution. As of 30 June 2019, the pharmaceutical network had 4,118 members, comprising 421 Group companies and 3,697 general members, an increase of 328 from the end of the previous fiscal year.」

「As of 31 March 2019, the pharmaceutical network had 3,790 members, comprising 3,729 dispensing pharmacies and 61 hospitals and clinics, an increase of 1,281 from the end of the previous fiscal year. This substantially exceeded the membership target of 3,200 for the current fiscal year.」

「Against the backdrop of the Guidelines for Improving Pharmaceutical Distribution taking effect in April 2018, demand for the distribution efficiency initiatives pursued by this business increased. Together with the steady increase in new members and other factors, this resulted in revenue of ¥2,897 million, up 8.3% year on year, and operating profit of ¥1,697 million, up 17.5%. As of 31 December 2018, the pharmaceutical network had 3,430 members, comprising 3,369 dispensing pharmacies and 61 hospitals and clinics, an increase of 921 from the end of the previous fiscal year, achieving the membership target of 3,200 for the end of the current fiscal year ahead of schedule.」

「In this business, revenue increased 5.2% year on year to ¥1,818 million and operating profit increased 13.5% to ¥1,060 million, mainly due to higher order-processing fee income accompanying the steady increase in new members. As of 30 September 2018, the pharmaceutical network had 2,976 members, comprising 2,917 dispensing pharmacies and 59 hospitals and clinics, an increase of 467 from the end of the previous fiscal year.」

「In this business, revenue increased 9.1% year on year to ¥955 million and operating profit increased 17.7% to ¥554 million, mainly due to higher order-processing fee income accompanying the steady increase in new members. As of 30 June 2018, the pharmaceutical network had 2,723 members, comprising 2,665 dispensing pharmacies and 58 hospitals and clinics, an increase of 214 from the end of the previous fiscal year.」

「As of 31 March 2018, the pharmaceutical network had 2,509 members, comprising 2,453 dispensing pharmacies and 56 hospitals and clinics, an increase of 739 from the end of the previous fiscal year. This substantially exceeded the membership target of 2,200.」

「As of 31 December 2017, the pharmaceutical network had 2,293 members, comprising 2,238 dispensing pharmacies and 55 hospitals and clinics, an increase of 523 from the end of the previous fiscal year.」

「In this business, revenue increased 6.9% year on year to ¥1,728 million and operating profit increased 11.4% to ¥934 million, mainly due to higher order-processing fee income accompanying the steady increase in new members. As of 30 September 2017, the pharmaceutical network had 2,012 members, comprising 1,974 dispensing pharmacies and 38 hospitals and clinics, an increase of 242 from the end of the previous fiscal year. Membership reached 2,000 in the 19th year since the service began in September 1999. The pace of membership growth has accelerated in recent years, with the total reaching 2,000 only four years and eight months after passing 1,000 in January 2013.」

「Although order-processing fee income increased as the number of new members rose substantially and annual net additions reached a record high, revenue was unchanged year on year at ¥3,237 million and operating profit declined 3.3% to ¥1,718 million, due to the leveling off of sales of hepatitis C treatments, sluggish systems sales, depreciation expenses related to the construction of the core system and other factors. As of 31 March 2017, the pharmaceutical network had 1,770 members, comprising 1,736 dispensing pharmacies and 34 hospitals and clinics, an increase of 370 from the end of the previous fiscal year.」

「In this business, revenue declined 0.8% year on year to ¥2,411 million, as higher order-processing fee income accompanying the steady increase in new members was offset by sluggish systems sales and other factors. Operating profit declined 5.0% to ¥1,280 million, reflecting depreciation expenses related to the construction of the core system and an increase in personnel to strengthen the sales organization. As of 31 December 2016, the pharmaceutical network had 1,668 members, comprising 1,635 dispensing pharmacies and 33 hospitals and clinics, an increase of 268 from the end of the previous fiscal year.」

「In this business, revenue increased 7.3% year on year to ¥1,617 million, mainly due to higher order-processing fee income accompanying the steady increase in new members and solid systems sales. Operating profit declined 0.6% to ¥838 million, reflecting depreciation expenses related to the construction of the core system and an increase in personnel to strengthen the sales organization. As of 30 September 2016, the pharmaceutical network had 1,597 members, comprising 1,564 dispensing pharmacies and 33 hospitals and clinics, an increase of 197 from the end of the previous fiscal year.」

「In this business, revenue increased 13.1% year on year to ¥851 million and operating profit increased 3.2% to ¥439 million, mainly due to higher order-processing fee income accompanying the steady increase in new members and solid sales of systems. As of 30 June 2016, the pharmaceutical network had 1,501 members, comprising 1,464 dispensing pharmacies and 37 hospitals and clinics, an increase of 101 from the end of the previous fiscal year.」

「Expansion of the Pharmaceutical Network」